Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone: a novel anthracycline derivative.

J Koeller1, M Eble

  • 1College of Pharmacy, University of Texas, Austin.

Clinical Pharmacy
|August 1, 1988
PubMed
Summary

Mitoxantrone, an anthracenedione agent, shows antitumor activity against leukemia, lymphoma, and breast cancer by interacting with DNA topoisomerase II. Its clinical use is limited by cardiotoxicity, cost, and FDA approval status.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Terrorist attack training exercise-What can be learned? : Baden-Württemberg counterterrorism exercise (BWTEX)].

Der Anaesthesist·2020
Same author

[Acute extended supply of inhalative oxygen in a pandemic].

Der Anaesthesist·2020
Same author

Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents - Recommendations of the GPOH-NPC Study Group.

Klinische Padiatrie·2016
Same author

A multicenter analysis of 123 patients with recurrent rectal cancer within the pelvis.

Frontiers of radiation therapy and oncology·2004
Same author

[The time-course of action of rapacuronium and mivacurium after early reversal following equally lasting relaxation].

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS·2003
Same author

Influence of extracorporeal irradiation on the reintegration of autologous grafts of bone and joint. Study in a canine model.

The Journal of bone and joint surgery. British volume·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Mitoxantrone is an anthracenedione agent synthesized in 1979.
  • It exhibits antiviral, antibacterial, immunomodulatory, and antitumor properties.
  • Its antitumor mechanism involves DNA topoisomerase II interaction and potential electrostatic interactions with human cells.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage, administration, and adverse effects of mitoxantrone.
  • To evaluate mitoxantrone's role in treating various cancers.

Main Methods:

  • Literature review of mitoxantrone's properties and clinical applications.
  • Analysis of clinical efficacy data in leukemia, lymphoma, and breast cancer.
  • Assessment of pharmacokinetic and safety profiles.

Main Results:

  • Mitoxantrone demonstrates significant efficacy in acute nonlymphocytic leukemia (30% response rate as a single agent, up to 60% in combination regimens).
  • In breast cancer, response rates are 25-30% as a single agent and over 60% in combination.
  • Common adverse effects include cardiotoxicity, myelosuppression, nausea, vomiting, stomatitis, mucositis, and alopecia.

Conclusions:

  • Mitoxantrone is an effective agent for leukemia, lymphoma, and breast cancer.
  • Its use is often restricted due to high cost and potential cardiotoxicity.
  • Limited FDA approval restricts its application primarily to acute nonlymphocytic leukemia.

Related Experiment Videos